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PENGHASILAN BAKTERIOSIN SF OLEH LACTOBACILLUS GASSERI SF 
UNTUK APLIKASI KULIT YANG DIJANGKITI BAKTERIA DAN 
PENYEMBUHAN LUKA  
 
ABSTRAK 
 
Enam belas strain Lactobacillus dan Bifidobacterium telah disaring berdasarkan 
pertumbuhan di dalam susu skim. B. longum 8643, L. plantarum 8943, L. casei 1268, L. 
fermentum 8312, L. fermentum 8848, dan L. gasseri SF menunjukkan kemandirian yang 
lebih tinggi (P< 0.05), dan ekstrak extrasel daripada enam strain ini juga mengandungi 
bioaktif pada konsentrasi yang mampu meningkatkan kesihatan kulit. Di samping itu, 
protein mentah yang diperolehi daripada ekstrak extrasel juga menunjukkan aktiviti 
penghambatan yang lebih tinggi (P< 0.05) terhadap pertumbuhan patogen kulit, dan 
mungkin disebabkan oleh sebatian antimikrob protein. Unsur seperti bakteriosin yang 
dihasilkan oleh L. gasseri SF menunjukkan aktiviti penghambatan yang lebih tinggi 
terhadap Enterococcus faecalis FM 2138, dan memenuhi ciri-ciri bakteriosin kelas II, 
justeru dinamakan sebagai bakteriosin SF. Bakteriosin SF juga didapati stabil haba 
dengan jisim molekul ketara sebanyak 3.5 kDa. Bakteriosin SF pada kepekatan 10240 
AU/mL juga mengurangkan cas negatif pada permukaan sel E. faecalis FM 2138 dengan 
signifikan (P <0.05), dan seterusnya menyebabkan depolarisasi membran dan 
pembentukan liang seni, seperti yang ditunjukkan dalam mikrograf elektron. Bakteriosin 
SF juga menurunkan tahap ungkapan mRNA dalam gen yang berkaitan dengan fsr korum 
penderiaan dan pembentukan biofilem dalam E. faecalis FM 2138. Potensi bakteriosin 
SF dalam penyembuhan luka juga telah dipamerkan in vitro, di mana bakteriosin SF pada 
kepekatan 5120 AU/mL meningkatkan proliferasi dan migrasi sel HaCaT dengan 
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signifikan (P< 0.05). Bakteriosin SF juga telah meningkatkan tahap ungkapan mRNA 
untuk faktor pertumbuhan (FGFR-IIIb) dan sitokin (TGF-β1 dan IL-8) yang memainkan 
peranan penting dalam proses penyembuhan luka. Selanjutnya, arnab yang dirawat 
dengan rumusan topikal yang mengandungi bakteriosin pada kepekatan 5120 AU/mL 
tidak mempamerkan sebarang tanda-tanda kerengsaan kulit dan perubahan histologi. 
Rumusan topical bakteriosin SF ini juga meningkatkan kadar pengecutan luka, 
kandungan hydroksiprolin, dan mengurangkan pertumbuhan E. faecalis FM 2138 dengan 
signifikan (P < 0.05) pada bahagian luka kulit tikus. Ungkapan mRNA untuk CX3CR1, 
IL- 8, dan TGF- β1, dan tahap ungkapan protein untuk IL- 8, TGF- β1, dan IFN- α juga 
telah dipertingkatkan semasa rawatan topical bakteriosin SF, menunjukkan bahawa 
bakteriosin SF boleh menggalakkan penyembuhan luka dengan mempengaruhi efektor 
imun yang terlibat dalam penyembuhan luka. Secara keseluruhan, keputusan dalam kajian 
ini mencadangkan bahawa bakteriosin SF pada kepekatan 5120 AU/mL adalah selamat, 
berkesan untuk menghambat pertumbuhan E. faecalis FM 2138 dan menggalakkan 
penyembuhan luka. Justeru, bakteriosin SF berpotensi digunakan dalam bidang 
dermatologi sebagai bahan bioaktif yang berkesan untuk mengatasi jangkitan E. faecalis 
dan/atau rawatan penjagaan luka. 
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PRODUCTION OF BACTERIOCIN SF BY LACTOBACILLUS GASSERI SF 
FOR USE IN DERMAL BACTERIAL INFECTION AND WOUND HEALING 
 
ABSTRACT 
 
Sixteen strains of Lactobacillus and Bifidobacterium were screened based on their growth 
in reconstituted skimmed milk. However, six strains (B. longum 8643, L. plantarum 8943, 
L. casei 1268, L. fermentum 8312, L. fermentum 8848, and L. gasseri SF) exhibited 
significantly higher viability (P< 0.05). Extracellular extracts of these strains contained 
bioactives at concentrations capable of promoting dermal health. Meanwhile, crude 
protein fractions fractionated from extracellular extracts of all six strains exhibited 
significantly higher antagonistic activity on skin pathogens, probably due to the 
production of putative bacteriocins. Putative bacteriocin produced from L. gasseri SF 
exhibited significantly higher (P< 0.05) antagonistic activity on Enterococcus faecalis 
FM 2138, and fitted the characteristics of class II bacteriocin and was thus renamed as 
bacteriocin SF. Bacteriocin SF was found to be heat-stable, with an apparent molecular 
mass of 3.5 kDa. Bacteriocin SF at a concentration of 10240 AU/mL significantly reduced 
(P< 0.05) the negative charge on the cellular surface of E. faecalis FM 2138, subsequently 
leading to membrane depolarization and pore formation, as visible in electron 
micrographs. Bacteriocin SF also down-regulated mRNA expression levels of fsr quorum 
sensing- and biofilm associated genes of E. faecalis FM 2138. Wound healing potential 
of bacteriocin SF was also demonstrated in vitro, where bacteriocin SF at a concentration 
of 5120 AU/mL significantly increased (P< 0.05) HaCaT cells proliferation and migration. 
Bacteriocin SF also increased the mRNA expression of growth factor (FGFR2-IIIb), and 
protein expression level of cytokines (TGF-β1 and IL-8) in HaCaT cells that play an 
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important role in wound healing. Furthermore, rabbits treated with a topical formulation 
containing 5120 AU/mL of bacteriocin SF exhibited no signs of skin irritation or 
abnormal histological changes. This topical bacteriocin SF formulation also significantly 
increased (P< 0.05) the wound contraction rate, hydroxyproline content, and reduced the 
viability of E. faecalis FM 2138 in the wound sites of mice. mRNA expression of 
CX3CR1, IL-8, and TGF-β1, and protein expression levels of IL-8, TGF-β1, IFN-α in 
mice were also elevated during topical bacteriocin SF treatment, indicating that 
bacteriocin SF may promote wound healing by regulating the immune effectors that are 
involved in wound healing. Collectively, results in this study suggest that bacteriocin SF 
at a concentration of 5120 AU/mL is safe, effectively inhibits the growth of E. faecalis 
FM 2138 and promotes wound healing. Therefore, bacteriocin SF could be potentially 
applied in the field of dermatology as a bioactive ingredient against E. faecalis infections 
and/or wound care treatment.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
1.1 Background 
Lactobacilli and bifidobacteria are the most common genera of bacteria with 
claimed probiotic properties. Probiotics are defined as “live microorganisms which 
when administered in adequate amounts, confer health benefits on the host” (Guarner et 
al., 2005). The health benefits of these bacteria in the gut have been well documented, 
including therapeutic restoration of altered gut microbiota; and prevention and treatment 
for diarrhea (Fung et al., 2011). Although major studies have traditionally focused on 
the potential beneficial effects of probiotics on gut health, there has been a shift in 
recent years toward discovering the therapeutic possibilities of probiotics beyond the 
gut, such as the skin.   
 Skin is the largest organ of human body. For an adult, the total surface area and 
weight of skin area are about 1.75 m2 and 5 kg, respectively (Percival et al., 2012). The 
skin functions as a vital physical barrier that protects the human body’s underlying 
tissues from the external environment influences, such as ultraviolet and desiccation. 
The skin also communicates with the external environment to support a normal flora; 
and regulate water content, calcium homeostasis, and temperature in human body. In 
addition, the skin harbours an enormously complex immune system that is poised to 
react to toxins, infections, and injuries (Ilkovitch, 2011). However, under certain 
circumstances such as injury, infectious microorganisms can breach into the skin and 
produce an infection which is detrimental to wound healing. 
 Lactobacilli and bifidobacteria have been advocated for the treatment and 
prevention of a wide range of skin infections and skin diseases. Peral et al. (2010) have 
demonstrated that ingestion of viable Lactobacillus plantarum significantly reduced 
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wound bacterial number and promoted wound healing in diabetic and non-diabetic 
patients with chronic infected leg; while Yesilova et al. (2012) reported that eight week 
oral administration of a probiotic mix (L. acidophilus, L. casei, L. salivarius, and 
Bifidobacterium bifidum) significantly reduced serum cytokines IL-5, IL-6, IFN-γ and 
total serum IgE levels in children with moderate to severe atopic dermatitis (AD), a long 
term skin disorder that involves scaly and itchy rashes. Clinical studies also showed that 
consumption of viable L. rhamnosus GG in pregnant mothers with a strong history of 
AD significantly reduced the frequency of developing atomic dermatitis in the offspring 
during the first 7 years of life (Kalliomaki et al., 2007). Although viable cells appear to 
have more beneficial effects than non-viable ones, a significant number of clinical 
studies have revealed that treatment and prevention of skin disorders with viable 
Lactobacillus and Bifidobacterium strains as either a single strain or in combination 
with other probiotic strains has been less impressive. This may be due in part to the 
decrement of viability and/or functionality of Lactobacillus and Bifidobacterium strains 
during storage. Meanwhile, the latter mounting studies have also suggested the potential 
use of non-viable cells, and bioactive compounds derived from these strains for dermal 
applications, via both oral and topical approaches (Cinque et al., 2011; Oh et al., 2006). 
Therefore, in contrast to viable cells, non-viable cells and/or bioactive compounds 
derived from Lactobacillus and Bifidobacterium strains may be a better option due to 
their stability at room temperature, and in cases in which the application of viable cells 
can lead to the risk of bacteremia. 
Indeed, non-viable cells and/or bioactive compounds derived from Lactobacillus 
and Bifidobacterium strains have been demonstrated to exert dermal health-promoting 
effects. Daily oral administration of L. rhamnosus cell lysate for a month has been 
shown to aid children with resistant atopic eczema by decreasing irritation scores; while 
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daily topical application of cream containing B. longum sp lysate for 2 months has been 
reported to improve reactive skin by decreasing skin sensitivity and increasing skin 
barrier function (Hoang et al., 2010; Guéniche et al., 2010). Meanwhile, it is important 
to note that, lactobacilli and bifidobacteria produce bioactive compounds that inhibit the 
adhesion of Gram-positive and Gram-negative pathogenic bacteria to the intestinal 
epithelial cells, and thus protect intestinal epithelium against the development of 
infectious disease. Considering such beneficial effects, bioactive compounds produced 
from Lactobacillus and Bifidobacterium strains could also be applied in the field of 
dermatology to enhance skin health and treat skin infections. 
Therefore, bioactive compounds produced by lactobacilli and bifidobacteria 
could exhibit antimicrobial activity against skin pathogens and/or improve dermal 
health. Moreover, production and potential mechanism of action by which bioactive 
compounds from lactobacilli and bifidobacteria can promote dermal health are not well 
understood with the studies currently available. Although bioactive compounds which 
are produced from natural resources as in this study generally have less toxicity, 
evaluation on the side effects and elimination of the toxicity (if present) via an in vivo 
model is deemed necessary to verify their safety. In addition, the efficacy of bioactive 
compounds produced from lactobacilli and bifidobacteria on dermal health via in vivo 
model is scarcely reported. Thus, more in vitro studies are needed to better understand 
the production and potential mechanisms of action of these bioactive compounds 
produced from lactobacilli and bifidobacteria on dermal health, as well as their efficacy 
and safety via in vivo studies.   
 
 
 
 
4 
 
1.2 Aim and Objectives for Research 
 The main aim of this study was to evaluate the effects of dermal bioactives from 
lactobacilli and bifidobacteria on skin pathogens and dermal health. 
 
Specific and measureable objectives were: 
1.  To screen and select Lactobacillus and Bifidobacterium strains that are capable of  
excreting dermal bioactives. 
2.  To fractionate and characterize bioactives that are responsible for antimicrobial  
activity against skin pathogens for skin health. 
3.  To elucidate the mechanisms of action of selected bioactives against selected 
skin pathogen in vitro.  
4.  To evaluate the wound healing potential of selected bioactives on human  
keratinocytes in vitro.  
5.  To evaluate the safety and efficacy of topical cream containing selected bioactives 
via in vivo models. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Probiotics 
Probiotics are defined as “live microorganisms, which when administered in 
adequate amounts, confer a health benefit on the host” (Guarner et al., 2005). Although 
probiotics have been explored and consumed for centuries, they have only started to 
receive scientific popularity for the past two decades.  
Several aspects which contribute a microorganism to be defined as a probiotic 
include i. must be alive when administered, ii. must deliver a measured physiological 
benefit that requires substantiation by studies performed in the target host, iii. not 
necessarily oral administered, but could encompass other applications, iv. restriction in 
term of mode of action are not defined, v. not excluded from pharmaceutical and 
therapeutic application, and vi. taxonomically defined strains (Sanders, 2003). A wide 
range of microorganisms has been identified to exhibit probiotic properties (Table 2.1). 
Lactic acid bacteria (LAB) and Bifidobacterium strains, in particular, have gained 
increasing attention as a major group of probiotic bacteria, mainly attributed to their 
proven potentials in the food industry, human nutrition and feed production. Probiotics 
are most often incorporated into food and beverage products as dietary adjuncts, aimed 
at promoting gastrointestinal health and modulating immune functions in the gut 
(Marini and Krutmann, 2012). Although major areas of concerns have been the potential 
for gut health, a growing number of studies have revealed suggestive evidences that 
probiotics may offer benefits beyond the gut. 
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Table 2.1: Major identified microorganisms associated with probiotic properties. 
Lactobacillus 
L. acidophilus 
L. brevis 
L. casei 
L. crispatus 
L. curvatus 
L. delbrueckii subsp.bulgaricus 
L. fermentum 
L. gasseri 
L. johnsonii 
L. paracasei 
L. plantarum 
L. reuteri 
L. rhamnosus 
L. salivarius 
Bifidobacterium 
B. adolescentis 
B. animalis subsp. lactis 
B. bifidum 
B. breve 
B. infantis 
B. lactis 
B. longum 
B. thermophilum 
 
Enterococcus 
E. faecalis 
E. faecium 
 
Lactococcus 
L. lactis subsp. cremoris 
L. lactis subsp. lactis 
L. raffinolactis 
 
Leuconostoc  
L. mesenteroides 
 
Streptococcus 
S. thermophilus 
 
Pediococcus 
P. acidilactici 
Bacillus 
B. cereus 
B. coaugulans 
B. subtilis 
 
Clostridium 
C. butyricum 
 
Escherichia  
E. coli 
 
Propionibacterium 
P. freudenreichii 
P.jensenii 
 
Kluyveromyces 
K. lactis  
 
Saccharomyces  
S. boulardii  
S. cerevisiae 
Reprinted from Lew and Liong (2013); with permission from John Wiley and Sons (License number: 3673481412391 ) 
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2.1.1 Lactobacillus 
 The genus Lactobacillus is the largest group in the family of Lactobacteriaceae, 
comprising 185 recognized species and 28 subspecies identified to date (Euzeby, 2013). 
Lactobacilli are characterized as Gram-positive, non-spore forming, non-flagelated rod 
or coccobacilli in shape bacteria that usually contain genomic guanine-cytosine (GC) 
varies from 32 to 51 mol % (Otieno, 2011). All Lactobacillus species are members of 
LAB, which able to produce lactic acid as a major end product of the fermentation of 
carbohydrates. Lactobacilli have been found in different location of the gastrointestinal 
tract, oral cavity, and vagina of healthy women microbiota (Reuter, 2001, Munson et al., 
2004; Martin et al., 2007). Several studies have also reported that lactobacilli are among 
the most dominant bacteria distributed in the small intestine (Saito, 2004; Reuter, 2001; 
Molin et al., 1993). Lactobacillus gasseri, L. reuteri and L. rhamnosus have been 
identified as most commonly isolated Lactobacillus species from human small intestine 
(Reuter, 2001; Molin et al., 1993). Lactobacilli are not only found in the human body, 
but are also ubiquitous in environments where carbohydrate are available, such as fruits, 
vegetables, beverages, plant, plant materials, dairy products, fermented or spoiled food, 
sewage, manure, respiratory, gastrointestinal, and genital tracts of animals (Giraffa et al., 
2010). The members of Lactobacillus are able to grow optimally at the temperature and 
pH varies widely from 30 ˚C to 45 ˚C and pH in the range of 5.5 to 7.0 (Hutkins, 2006). 
Clinical evidences have revealed potential uses of Lactobacillus-containing food and 
beverages on human health promoting effects (Reid et al., 2003). Thus, lactobacilli have 
generally considered as beneficial microorganisms, and often incorporated into daily 
diet. 
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2.1.2 Bifidobacterium 
 The genus Bifidobacterium was historically classified as a member of LAB, and 
in the genus Lactobacillus based on their correlation of the peptidoglycan (PGN) 
structure (Kandler and Lauer, 1974). However, further studies have discovered that 
bifidobacteria degrade hexoses using a peculiar metabolic pathway, bifid shunt, which is 
also known as fructose-6-phosphate pathway (Wolin et al., 1998). Fructose-6-phosphate, 
the key enzyme in this pathway, has also listed as one of the main character for the 
taxonomically classification at genus level (Biavati and Mattarelli, 2001).  Therefore, in 
the 1970s, this group of bacteria has been reclassified into Bifidobacterium, which 
belongs to the family of Bifidobacteriaceae. Euzeby (2013) has reported that 47 species 
and 9 subspecies of the genus Bifidobacterium have been listed to date. 
 Bifidobacteria are Gram positive, non-motile, anaerobic and chemoorganotrophs 
bacteria, with genomic GC content between 42 and 67 mol % (Biavati and Mattarelli, 
2001; Delcenserie et al., 2007; Otieno, 2011). They commonly occur as singly, chains, 
or clumps. They could also occur in various shapes, including short, curved rods, club-
shaped rods, or bifurcated Y-shape rods (Gomes and Malcata, 1999). Bifidobacteria are 
able to grow optimally at temperatures ranging from 37 ˚C to 41 ˚C, and pH between 
pH 6.5 and 7.0 (Hutkins, 2006). Bifidobacteria have been successfully isolated from 
varies habitats in animals and human, such as feaces, honey bee intestine, rumen of 
cattle, and human vagina (Otieno, 2011).  Bifidobacteria have been documented as the 
most dominant bacteria that colonize the gastrointestinal tracts of human and animals, 
especially in breastfed infants. Bifidobacterium longum biovar infantis, B. breve and B. 
bifidum are represent up to 91 % of intestinal microbiota in breastfed infant and 3 - 7 % 
in adults (Biavati et al., 2000). Therefore, Bifidobacterium have been focused, and 
considered as one of the most common genera used for human consumption.  
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2.1.3 Conventional Health Benefits of Probiotics 
 Probiotics have a long history of safe use with fermented dairy products, since 
their beneficial effects on gastrointestinal health have been discovered. Indeed, 
maintenance of gastrointestinal health is crucial as approximately 70 % of all immune 
cells of the entire immune system are located in the gastrointestinal tract (Vighi et al., 
2008). Accumulating evidences also indicate that intestinal microbiota interacts with 
both innate and adaptive immune system, affecting different aspects of gastrointestinal 
physiology and function (Purchiaroni et al., 2013). Lactobacilli and bifidobacteria are 
among the Gram-positive bacterial populations that commonly inhabit in healthy 
intestinal microflora, and thus they have been the focus that are used in most of the 
studies for exploring and evaluating the roles of probiotics in the maintenance of 
gastrointestinal health.  
 Probiotics have been found to alleviate lactose intolerance symptoms by 
increasing the digestibility of lactose that is present in human intestine. In vitro studies 
have demonstrated that Lactobacillus strains are capable of exhibiting β-galactosidase, 
phospho-β-galactosidase and phospho-β-glucosidase activities, which hydrolyze lactose 
by activating two lactose transportation systems, namely lactose-permease 
transportation and lactose-specific phosphoenolpyruvate-dependent phosphotransferase 
system (Honda et al., 2007). It has been described that if lactose maldigesters ingested 
sufficient amount of lactose, gastrointestinal symptoms may result, including abdominal 
discomfort, bloating, diarrhea, and flatulence (Vesa et al., 2000). Additionally, Gaón et 
al. (1995) have performed a clinical study to evaluate the efficacy of milk fermented 
with L. acidophilus and L. casei on alleviating lactose intolerance symptoms and lactose 
digestion with 18 lactase deficiency subjects. The oral administration of milk fermented 
with Lactobacillus reduced the development of symptoms, suppressed intestinal motility, 
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and decreased hydrogen production intake, thereby leading to an improvement in 
lactose digestion. He et al., (2008) have also conducted a human trial with 11 Chinese 
lactose maldigesters to evaluate the effects of yogurt supplemented with B. animalis and 
capsule encapsulated with B. longum on the colonic microbiota. The authors found that 
ingestion of yogurt and capsule containing Bifidobacterium increased the numbers of 
Bifidobacterium in the colonic microbiota and reduced symptoms in lactose 
maldigesters. 
 Probiotics have also been investigated for their roles in treating irritable bowel 
syndrome (IBS). IBS is a functional bowel disorder that has been associated with 
complex pathophysiology; include microscopic inflammation, alterations in gut motility, 
and visceral hypersensitivity (Aragon et al., 2010). The common features associated 
with IBS include discomfort of defecation, abdominal pain, bloating, and abnormal 
bowel habit. Probiotics are seen as a promising therapy to alleviate IBS symptom due to 
their ability to reduce gut and fluid motility. Probiotics have been reported to 
deconjugate and absorb bile acid, which would subsequently reduce the colonic mucosal 
secretion of mucin and fluids that lead to functional diarrhea (Camilleri, 2006). 
Additionally, lactobacilli and bifidobacteria could reduce inflammation by exhibiting 
antimicrobial activities. Probiotics inhibited the growth and colonization of pathogenic 
bacteria via three possible mechanisms, including ability of adherence, production of 
inhibitory substances and iron-siderophore (Fung et al., 2011). Administration of VSL 
#3, a mixture of 8 probiotic strains in male IBS rats, have revealed that probiotics 
significantly reduced visceral pain perception via resetting colonic expression of subsets 
of genes mediating pain and inflammation (Distrutti et al., 2013). The administration of 
B. infantis 35624- fermented malted milk drink (1 x 1010 live bifidobacteria per day) is 
also capable of normalizing the abnormal ratio of an anti-inflammatory to pro-
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inflammatory cytokine (IL-10/IL-12), and resulting in significant reduction in IBS 
symptom scores (O’Mahony et al., 2005). Recent pilot study and meta-analysis also 
updated the significant reduction of common IBS symptoms, modulation of mucosa 
microbiota composition and immune functions in IBS patients treated with probiotics as 
compared to the placebo group (Ng et al., 2013; Ortiz-Lucas et al., 2013). 
In addition to reduction of IBS, the potential protective roles of probiotics 
against tumor development in the colon have also been established. Previous studies 
reported that probiotics could modulate toxifying and detoxifying enzymes associated 
with carcinogenesis by producing short chain fatty acids that decrease the pH of the 
colon (Lankaputhra and Shah, 1998). Another possible mechanism to reduce the risk of 
colon cancer could be attributed to the cell wall skeleton of the LAB that can bind with 
mutagens (Zhang and Ohta, 1991). Administration of probiotics has also found to 
suppress nitroreductase and β-glucoronidase activities, thus reduced aberrant crypt foci 
counts in carcinogen-induced rats (Verma and Shukla, 2013). Probiotics also modulate 
immune response by decreasing the gene expression of programmed cell death in 
colorectal tissues of carcinogen-induced rats (Mohania et al., 2013). Clinical studies 
have shown promising results in colon cancer therapy, particularly on polypectomized 
(removal of a polyp) patients and patients undergoing elective colorectal surgery. Rafter 
et al. (2007) have evaluated the effects of symbiotic food containing L. rhamnosus LGG 
and B. lactis BB 12 in 12 weeks randomized, double-blind study involving 43 
polypectomized  patients. Symbiotic intervention significantly increased secretion of IL-
2, changed feacal flora, decreased genotoxins, colorectal proliferation, and the capacity 
of fecal water to induce necrosis in colonic cells. Furthermore, Liu et al. (2011) 
conducted a double-blind study to determine the effects of perioperative administration 
of probiotics in 100 patients undergoing elective colorectal surgery. The authors found 
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that patients administered with probiotics significantly enhanced mucosal tight junction 
protein expression, increased transepithelial resistance, decreased transmucosal 
transmission of horseradish peroxidase, ileal-bile acid binding proteins and positive rate 
of blood bacterial DNA (risk of bacteremia).  
Other beneficial roles of probiotics in gastrointestinal health including the 
alleviation of inflammatory bowel disease, antibiotic-associated diarrhea, acute 
infection diarrhea, and postoperative complications have also been well documented 
(Fung et al., 2011, Sanders et al., 2013). 
 
2.1.4 New Roles of Probiotics 
 There is an increasing evidence to indicate that contemporary studies have 
focused more on the possible deployment of probiotics for treating extra-intestinal 
disorders due to their ability to balance intestinal microbiota, which ameliorated the 
immune systems at local and systemic levels. Indeed, several promising new roles of 
probiotics have been proposed in the past 5 years (Table 2.2). Thus far, emerging 
evidences have outlined more promising and significant impact of probiotics on gut-
brain-skin axis. 
Dinan et al. (2013) have defined psychobiotics as living organisms, when 
ingested in adequate amounts, exerts beneficial effects in patients suffering from 
psychiatric illness. The potential novel use of probiotics as psychobiotics has recently 
been proposed due to their ability to manage stress-related psychiatric disorders. 
Preliminary studies have revealed that certain probiotic strains are capable of producing 
and delivering neuroactive substances, such as gamma-aminobutryic acid, at a 
concentration level which may alleviate symptoms of depression and anxiety (Barrett et 
al., 2012). Additionally, Messaoudi et al. (2011) have conducted both pre-clinical and 
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clinical studies to investigate the anxiolytic-like activity of a probiotic formulation 
containing L. belveticus R0052 and B. longum R0175 in rats, and its possible 
psychotropic-like effects via a double-blind, placebo-controlled, randomized parallel 
study that involving 66 healthy volunteers. The authors found that administration of 
probiotic formulation for 2 weeks significantly reduced anxiety-like activity in rats, 
while administration of probiotic formulaiton for 30 days mitigated psychological 
distress (somatization, depression, anger-hostility, anxiety) in volunteers. Tillisch et al. 
(2013) also reported that consumption of fermented milk with probiotics for 4 weeks 
could change midbrain connectivity by reducing intrinsic activity of resting brain 
(affective, viscerosensory, and somatosensory cortices) in healthy women. Regarding 
the potential mechanistic pathway, it has been reported that consumption of probiotics 
may influence systemic cytokines and thus improved mood disturbance and fatigue 
which were induced by systemic administration of lipopolysaccharide endoxtoxin 
(Lakhan and Kirchgessner, 2010). Another possible mechanism by probiotics involved 
the production of antimicrobial compounds such as short chain fatty acids, which 
prevented the stress-induced alteration to overall intestinal microbiota (Logan et al., 
2003). The beneficial effects of probiotics on mental health may also be due to their 
ability to modulate neurotrophic chemicals including brain-derived neurotrophic factor 
(Logan and Katzman, 2005). All biochemical and behaviour evidences have led to the 
suggestion that they could be used as a psychotropic agent.  
In addition to the psychobiotic properties, potential roles of probiotics in the 
maintenance of skin health have also been highlighted. Preliminary studies have 
suggested that probiotics could produce dermal bioactives such as bacteriocins and 
lipoteichoic acid (LTA), and thereby inhibiting the growth of skin pathogens and/or 
enhancing skin defense system (Tan et al., 2014). In vitro studies have further 
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demonstrated that keratinocytes treated with lysates from Lactobacillus and 
Bifidobacterium strains could increase tight-junction barrier function via modulation of 
protein components such as claudin 3, while L. helveticus- fermented milk enhanced 
keratin-10 mRNA expression subsequently promoted cell differentiation (Baba et al., 
2006; Sultana et al., 2013). Feeding of B. breve strain Yakult to ultraviolet-induced 
hairless mice also decreased transepidermal water loss, suppressed oxidation levels of 
proteins and lipids by preventing the generation of reactive oxygen species (Ishii et al., 
2014). On the other hand, Jones et al., (2012) also found that topical application of an 
adhesive gas permeable patch containing nitric oxide gas-producing probiotic increased 
wound closure and accelerated wound healing in New Zealand white rabbit model of 
ischaemic and infected wounds. Clinical studies have reported on the promising effects 
of probiotics on dermal health. Guéniche et al., (2009) conducted a randomized, double 
blind placebo-controlled trial to determine the immunomodulatory effects of probiotics 
in 57 volunteers upon exposure to ultraviolet (2 x 1.5 minimal erythema dose). The 
authors reported that volunteer ingested L. johnsonii NCC 533 daily for 8 weeks 
significantly increased the production of regulating cytokines and growth factor such as 
TGF-β, which lead to the preservation of cutaneous immune homeostasis. Recently, K 
et al., (2014) also found that consumption of probiotics for 6 months could interact with 
neuropeptide S receptor 1 gene SNP hopo546333, and thus reduced the risk of IgE-
associated atopic eczema in early childhood. Altogether, current available evidences 
have illustrated the dermal potential of formulations containing living probiotics and/or 
probiotic-derived bioactives for skin maintenance.  
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Table 2.2 New roles and benefits of probiotic bacteria beyond the gut. 
 Roles and/or benefits Condition/ Location  Reference 
1 Suppress arthritic inflammation osteoarthritis So et al. (2011) 
2 Reduce risk factors for cardiovascular 
diseases 
cardiovascular 
diseases 
Ebel et al. (2014) 
3 Inhibit JUNV infection viral infection Martinez et al. (2012) 
4 Decrease body and fat pad weights obesity Park et al. (2013) 
5 Protect against asthma respiratory system Yu et al. (2010) 
6 Reduce plasma, aortic, and hepatic 
lipid profile 
hypercholesterolemia Mohania et al. (2013) 
7 Modulate lung immune functions lung Forsythe (2014) 
8 Protect against free radicals-induced 
disorders 
metabolic disorders Ghoneim and Moselhy 
(2013) 
9 Modulate bone health bone Rodrigues et al. (2012) 
10 Protect urogenital tract  renal Vujic et al. (2013) 
 
2.2 Human Skin  
2.2.1 Skin Structure and Function 
Skin is the largest organ of the human body and functions as a primary physical 
barrier that protects the host’s underlying tissues from external environmental 
influences such as bacterial infection, desiccation, ultraviolet irritation, physical as well 
as chemicals assaults, and excessive water loss. The human skin can be basically 
divided into two main layers, the dermis and the epidermis (Figure 2.1). The dermis is 
the thick inner layer and consists mostly of fibrous and amorphous connective tissues, 
such as elastic and collagen fibers that provide mechanical support, pliability, elastic 
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and tensile strength to the skin (Prost-Squarcioni et al., 2008). The epidermis is the 
outer layer of dense epithelial keratinocytes, which undergo keratinization to maintain 
the integrity of epithelial tissues and serve as an effective protective barrier (Presland 
and Dale, 2000). 
The effective physical barrier is predominantly located in the outermost layer of 
epidermis, the stratum corneum (SC). The stratum corneum is 10 - 20 μm thick, and 
formed when keratinocytes from the stratum basale begin to differentiate, migrate 
towards the upper layers (stratum spinosum, and stratum granulosum), and transform 
into continuous sheets of flattened and anucleated cells (corneocytes), at the end of the 
keratinization process (WHO, 2009). Corneocytes are composed mainly of insoluble 
bundled keratin filaments that are surrounded by cornified envelope proteins filled with 
inoculcrin, loricrin, filaggrin and cornified lipid envelope, which are important for the 
mechanical stability and chemical resistance of the cells (Proksch and Jensen, 2012). 
Corneocytes are embedded in a hydrophobic lipid-rich intercellular space that is 
composed of ceramides, free saturated fatty acids, cholesterol, and organized as lamellar 
lipid layers, which increased the cohesion between the cells, and thereby contributes to 
making the epidermis a competent barrier (WHO, 2009). In the normal human 
epidermis, the balanced processes of cellular proliferation and desquamation facilitated 
the reduction of cohesion between corneocytes, and resulted in a complete renewal of 
stratum corneum (Proksch and Jensen, 2012). 
In addition to stratum corneum, nucleated epidermis, in particular the 
desmosomes and tight junctions also contribute to the barrier function of skin. It has 
been demonstrated that desmosomal and adherence junction proteins such as E-cadherin 
is essential due to their ability to retain a functional epidermal water barrier by 
stabilizing the adhesion between the cells (Tunggal et al., 2005). Furthermore, the 
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presence of tight junction protein such asoccludins and claudins could lead to a proper 
separation between apical and basolateral part of a cell, which prevented the alteration 
of epidermal function (Furuse et al., 2002). The importance of nucleated epidermal 
layers in preventing the entry of harmful substances into the skin has also been reported 
(Baroni et al., 2012). Taken together, stratum corneum and nucleated epidermis plays an 
irreplaceable role in maintaining the skin barrier function. 
 
   Figure 2.1 Skin layer and its regular resident cells. Reprinted from Beutler Lab (2011). 
 
2.2.2 Skin Microbiota 
In addition to physical barrier function, human skin also acts as an intricate 
habitat, harbouring a dynamic and diverse population of microorganisms, which is 
known as the skin microbiota (Hannigan and Grice, 2013). The advanced technology in 
DNA sequencing and metagenomics have provide new insights on the studies of human 
skin microbiota, by facilitating a greater identification method of the microorganisms; 
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and thorough investigation approach on the interaction between skin microbiota and 
skin diseases. Archaea, bacteria, fungi, and viruses constitute the skin microbiota. Grice 
et al. (2009) have characterized the topography diversity of healthy human skin 
microbiota via the use of 16S rRNA gene phylotyping. A total of 19 phyla were found 
from the samples of twenty diverse skin sites in 10 healthy humans, and the identified 
microorganisms were mostly classified into four bacterial phyla, Actinobacteria 
(51.8 %), Bacteroidetes (6.3 %), Firmicutes (24.4 %), and Proteobacteria (16.5 %).  
Bacterial population on human skin can be categorized as resident (reproducing, 
growing), temporary resident (not typically resident, yet can colonize), and transient 
(contaminant, non-reproducing). Consistent with previous studies, 16S RNA gene 
phylotyping also listed Staphylococcus epidermidis, S. aureus, Corynebacterium 
diphtheria, C. jeikeium, and Propionibacterium acnes as normal resident of cutaneous 
bacteria (Cogen et al., 2007; Findley et al., 2013). Despite these bacteria are abundant 
populations of the normal skin microbiota, Grice et al. (2009) have reported that the 
bacterial communities are distributed in a range of physiologically and topographically 
distinct niches, with sebaceous sites being the most stable. Sebaceous sites were 
predominantly Staphylococcus spp and Propionibacterium, whereas moist sites were 
found to be predominantly resided by Staphylococcus and Corynebacterium. 
 Skin microbiota is not only limited to bacteria, fungi also represent as a major 
population in the normal human skin. Findley et al. (2013) have explored topographical 
map of the fungal diversity on 14 skin sites in 10 healthy adults, using intervening 
internal transcribed spacer 1 region and 18S rRNA sequencing methods. Authors found 
that eleven core-body and arm sites were dominated by 11 Malassezia species, and sites 
on the feet shown the richest fungal diversity among all the body sites. Recently, a 
whole metagenomic analysis also discovered the cutaneous viral population- human 
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polyomaviruses in the healthy individuals (Foulongne et al., 2012). 
Advanced molecular analyses revealed that skin microbiota may intervene in the 
disruption of skin homeostasis, subsequently raise the risk for dermatological diseases. 
Although S. aureus is one of the normal residents on human skin, it is likely in part 
contributed to AD, which is a chronic inflammatory skin disease that frequently occurs 
in children. Park et al. (2013) have reported that AD patients were heavily colonized by 
S. aureus. The S. aureus colonization rates in acute and chronic skin lesions of 687 AD 
patients (188 infants, 267 children, and 232 adults) were 71 % and 35 % higher as 
compared to 247 control urticarial patients without any skin lesions. Enterococcus and 
Corynebacterium were also significantly higher in the lesions than non-lesional skin of 
AD in Saudi children (Bilal et al., 2013). On the other hand, evolving evidences have 
suggested the potential role of P. acnes in acne vulgaris, which is a common skin 
disorder associated with abnormal sebum production, bacterial proliferation and 
inflammation. A current study has identified 71 strains of P. acnes in different skin sites 
of acne patients, and acne-associated genes were also found to be located in different 
chromosomal loci of the bacterial genome, thereby highlighting that there may 
contribute to acne pathology (Fitz-Gibbon et al., 2013). Dysbiosis of the skin 
microbiota have been implicated in the pathogenesis of psoriasis which may cause 
excessive growth of skin cells and chronic inflammation. Fahlen et al. (2012) have 
compared bacterial microbiota in skin biopsies from normal and psoriasis patients with 
massive parallel pyrosequencing targeting the 16S rRNA gene and the variable regions 
V3-V4. Results shown that Streptococcus spp, including S. pyogenes was present at 
significantly higher level in psoriasis, whereas staphylococci and propionibacteria were 
significantly lower in psoriasis as compared to normal skin.  
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 Additionally, bacteria are also known as the most common microorganisms 
associated with wound infections. Previous studies have reported that Escherichia coli, 
Klebsiella spp, S. aureus, Micrococcus luteus, and Enterococcus faecalis are most 
frequently found in both post-operative wounds and minor wound infections (Ranjan et 
al., 2010; Malic et al., 2009; Giacometti et al., 2000). Fadeyibi et al. (2013) have also 
demonstrated that 53.6 % of the infected burn wounds in burns patients were infected 
with Gram-negative bacteria, Pseudomonas aeruginosa. 
 
2.2.3 Skin Defense Mechanisms  
 Human skin is more than a mere physical protective barrier against  
environmental challenges; it also has a formidable function to protect the epidermal 
integrity via a panoply of defense mechanisms, aimed  at controlling invading microbial 
pathogens. The skin defense mechanisms consist of innate immunity, which mediates 
the initial rapid elimination of pathogens; and adaptive immunity, which generates 
highly specific second line of defense as well as immunological memory (Kang et al., 
2006). Although both of the innate and the adaptive immune systems have distinct 
function, there is coordinated effort between these systems, which defines the effective 
immune responses.  
 The innate immune system in skin consists of a range of pre-existing readily 
mobilized cells, and preformed nonspecific and broadly specific effector molecules 
(Oppenheim et al., 2003). When pathogenic bacteria succeed in breaching the skin 
barrier, toll like receptors (TLRs) and other pattern recognition receptors that are 
expressed by readily mobilized cells start to recognize pathogen-associated molecule 
patterns (PAMPs). Keratinocytes have been shown to express TLRs 1, 2, 4, 5 and 9, 
which can recognize exogenous PAMPs including lipopeptides (TLR 1,2), phenol-
21 
 
soluble modulin (TLR 2), PGN (TLR 2), lipopolysaccharide (LPS) (TLR 2,4), flagellin 
(TLR 5), and hypomethylated CpG (TLR 9) from pathogenic bacteria, through myeloid 
differential factor 88 dependent pathway (Miller, 2008). These recognitions result in the 
activation of nuclear factor-κB (NF-κB), and subsequently release and/or stimulate the 
production of effector molecules, in particular, antimicrobial peptides (AMPs) and 
antimicrobial enzymes. AMPs are pivotal defense molecules of the cutaneous innate 
immune system, which act as endogenous antibiotics against a broad spectrum of 
pathogenic bacteria (Gallo and Huttner, 1998). Two major families of small cationic 
AMPs (< 100 amino acids, 3 - 5 kDa) that are synthesized and/or released from 
keratinocytes and neutrophils are the β-defensins and the cathelicidins. The cationic and 
amphiphilic characteristics of the β-defensins and cathelicidins have been suggested to 
contribute to the antimicrobial action, by disrupting the membrane integrity and altering 
the intracellular function of pathogenic Gram-negative and Gram-positive bacteria 
(Oppenheim et al., 2003). In human skin, β-defensin-1 (hBD-1, 36 amino acids, 3.9 kDa) 
is constitutively synthesized by keratinocytes, whereas hBD-2 (41 amino acids, 4.3 
kDa), hBD-3 (45 amino acids, 5.1 kDa) and the cathelicidins are presented at lower 
level in keratinocytes, but can be upregulated during inflammation and accumulated at 
sites of infection through release by neutrophils (Braff et al., 2005). 
Accumulative studies have demonstrated the roles of human β-defensins and 
cathelicidins as AMPs in skin defense. hBD-1 has been shown to exhibit antimicrobial 
activity against Gram-negative bacteria such as P. aeruginosa and E. coli (Pivarcsi et al., 
2005). Although hBD-1 is constitutively expressed, Sorensen et al. (2005) have reported 
that expression of hBD-1 in epidermal keratinocyte cultures can be increased upon 
stimulation with LPS, PGN or SpeB, a cysteine proteinase from S. pyogenes. On the 
other hand, Dinulos et al. (2003) found that hBD-2 could have potent antimicrobial 
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activity against skin pathogenic bacteria, particularly high adherent strains of S. 
pyogenes and S. aureus, but not skin commensal bacteria such as S. epidermidis. The 
expression of hBD-2 was also induced consistently by tumor necrosis factor alpha 
(TNF-α), IL-1β, and both Gram- positive and negative bacteria including S. aureus, E. 
coli, and P. aeruginosa (Schroder and Harder, 1999; Dinulos et al., 2003). Furthermore, 
Lai et al. (2010) have reported that a sterile non-toxic small molecule (< 10 kDA) of S. 
epidermidis activated TLR 2 signaling, subsequently enhancing the hBD-2 mRNA 
expression, and increasing the capacity of cell lysates to inhibit the growth of S. aureus 
and group A Streptococcus (GAS). Meanwhile, hBD-3 demonstrated a broad spectrum 
of antimicrobial activity against potent pathogen bacteria, including methicillin-resistant 
S. aureus (MRSA) (Harder and Schroder, 2005). An in vitro study indicated that S. 
aureus and LTA-induced the expression of hBD-3 through TLR 2 signaling and 
activation of mitogen-activated protein kinase (Menzies and Kenoyer, 2006). hBD-3 has 
also shown the ability to bind to lipid II-rich sites of cell wall biosynthesis of MRSA, 
which may lead to perturbation of the biosynthesis machinery and result in localized 
lesions in the cell wall (Sass et al.. 2010). Another important AMPs on skin, human 
cathelicidin antimicrobial protein 18 (hCAP18) or its mature form, AMP LL-37 (37 
amino acids, 4.5 kDa) has also exhibited rapid antimicrobial activity against S. aureus, 
E. faecalis and P. aeruginosa (Nizet and Gallo, 2003). Although the production of LL-
37 is very low in normal keratinocytes, its production can be dramatically increased in 
response to wounding and upon challenge with S. pyogenes (Dorschner et al., 2001). 
 Besides their microbicidal functions, hBDs and cathelicidins could extend their 
roles as “alarmins” to other aspects of immunity in inflamed skin and/or wound repair 
process. Niyonsaba et al. (2007) have performed a study to investigate whether hBDs 
participate in cutaneous inflammation and wound healing. Authors found that hBD-2 
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and hBD-3 stimulated the production of pro-inflammatory cytokines and chemokines 
(IL-6, IL-10, and monocyte chemoattractant protein-1). They also demonstrated that 
hBD-2 and hBD-3 elicited intracellular Ca2+ mobilization, induced phosphorylation of 
epidermal growth factor receptor, and signal transducer and activator of transcription, 
subsequently increasing keratinocyte migration and proliferation. Although hBD-1 is 
structurally closer to hBD-2 and hBD-3, it has no effect on the release of cytokines and 
cell proliferation. In contrast, LL-37 has shown strong chemotactic activity for cluster of 
differentiation 4 expressed on the surface of helper T lymphocytes (CD4+ T 
lymphocytes) (Agerberth et al., 2000). LL-37 bridges the innate and adaptive immune 
system, by influencing dendritic cells (DCs) differentiation, and enhancing secretion of 
T helper-1 (Th-1) inducing cytokines via the activation of CD4+ T lymphocytes 
(Davidson et al., 2004). In vitro studies suggest that LL-37 could also stimulate 
angiogenesis on endothelial cells via activation of formyl peptide receptor 1, increase 
proliferation and formation of vessel-like structure (Koczulla et al., 2003). Therefore, 
LL-37 plays several crucial roles in re-epithelialization and wound healing on human 
skin.   
 Another effector molecule with potential importance in human skin defense is 
lysozyme (14 - 15 kDa), an antimicrobial enzyme. Lysozyme is a PGN N-acetyl-
muramoylhydrolase, also known as muramidase. The substrate of lysozyme is PGN, 
which is an abundant component responsible for the rigidity of the bacterial cell wall. 
Lysozyme has been reported as a lytic enzyme that cleaves the bond between N-
acetylglucosamine and N-acetylmuramic acid of the PGN in the Gram-positive bacterial 
cell wall, and results in cell lysis (Niyonsaba and Ogawa, 2005). Previously, Ogawa et 
al. (1971) have found lysozyme in human skin, and the content was three-fold higher in 
the epidermal than the dermal layer. Gram-positive bacteria have a thick layer of PGN 
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whereas Gram-negative bacteria have a thin layer of PGN surrounded by outer 
membrane that acts as a protective barrier (Masschalck and Michiels, 2003). Therefore, 
lysozyme is more active against Gram-positive pathogenic bacteria. However, 
Masschalck and Michiels (2003) have also reported that the antimicrobial spectrum of 
lysozyme can be extended till Gram-negative bacteria via the use of outer membrane 
permeabilizing agent such as ethylenediaminetetraacetic acid (EDTA) or polycations. In 
addition to their role as antimicrobial, lysozyme has also been shown to enhance 
phagocytic activity of polymorphonuclear leukocytes, and control skin inflammation 
(Ibrahim et al., 2001; Ganz et al., 2003). 
 The activation of TLRs not only produces AMPs and lysozyme, but also bridge 
innate and adaptive immunity. PAMP recognition by TLRs on DCs, mediates DCs 
maturation and initiates adaptive T cell and B cell immunity (Lai and Gallo, 2009). In 
normal uninflamed skin, DCs are well positioned in both epidermis (Langerhan cells) 
and dermis (dermal DCs), and incapable of initiating T cell immunity. Using a mice 
model of skin infection, Igyarta et al. (2011) have shown that DCs become activated 
and migrated from the site of injury or infection to regional lymph nodes, resulting in 
the generation of antigen-specific Th-17 and Th-1 cells. These T helper cells responses 
are essential for the host to orchestrate sufficient defensive mechanism to control 
inflammation. Th-17 cells produce IL-17 and enhance host defense against extracellular 
pathogenic bacteria at the epidermal surface, whereas Th-1 cells produce interferon 
gamma and enhance cell-mediated immunity against intracellular pathogenic bacteria 
(Tesmer et al., 2008). The activation of DCs also stimulates B cells to proliferate, 
differentiate into plasma cells and secret immunoglobulins, which are used by the host’s 
immune system to identify and neutralize pathogenic bacteria (Wykes and Macpherson, 
2000). 
